References
- Fuchs C, Mitchell EP, Hoff PM. Irinotecan in the treatment of colorectal cancer. Cancer Treat Rev 2006; 32: 491–503
- De Jong FA, Scott-Horton TJ, Kroetz DL, McLeod HL, Friberg LE, Mathijssen RH, et al. Irinotecan-induced diarrhea: Functional significance of the polymorphic ABCC2 transporter protein. Clin Pharmacol Ther 2007; 81: 42–9
- Van der Bol JM, Mathijssen RHJ, Loos WJ, Friberg LE, van Schaik RHN, de Jonge MJA, et al. Cigarette smoking and irinotecan treatment: Pharmacokinetic interaction and effects on neutropenia. J Clin Oncol 2007; 25: 2719–26
- Sevilla Garcia I, Rueda A, Alba E. Irinotecan-induced central nervous system toxicity: A case report. J Natl Cancer Inst 1999; 91: 647
- Baz DV, Bofill JS, Nogueira JAM. Irinotecan-induced dysarthria. J Natl Cancer Inst 2001; 93: 1419–20
- Ceccaldi B, Kara F, Mommeja-Marin H, Bègue M, Saint Blancard P, Le Marec E, et al. Dysarthrie lors de l'administration d'irinotecan. Rev Med Interne 2002; 23: 950–1
- De Marco S, Squilloni E, Vigna L, Bertagnolio MF, Sternberg CN. Irinotecan chemotherapy associated with transient dysarthria and aphasia. Ann Oncol 2004; 15: 1147–8
- Hamberg P, Donders RCJM, Ten Bokkel Huinink D. Central nervous system toxicity induced by irinotecan. J Natl Cancer Inst 2006; 98: 219
- Blaney SM, Takimoto C, Murry DJ, Kuttesch N, McCully C, Cole DE, et al. Plasma and cerebrospinal fluid pharmacokinetics of 9-aminocamptothecin (9-AC), irinotecan (CPT-11), and SN-38 in nonhuman primates. Cancer Chemother Pharmacol 1998; 41: 464–8
- Noble CO, Krauze MT, Drummond DC, Yamashita Y, Saito R, Berger MS, et al. Novel nanoliposomal CPT-11 infused by convection-enhanced delivery in intracranial tumors: Pharmacology and efficacy. Cancer Res 2006; 66: 2801–6
- Chamberlain MC. Salvage chemotherapy with CPT-11 for recurrent glioblastoma multiforme. J Neurooncol 2002; 56: 183–8
- Cloughesy TF, Filka E, Kuhn J, Nelson G, Kabbinavar F, Friedman H, et al. Two studies evaluating irinotecan treatment for recurrent malignant glioma using an every-3-week regimen. Cancer 2003; 97: 2381–6
- Raymond E, Fabbro M, Boige V, Rixe O, Frenay M, Vassal G, et al. Multicentre phase II study and pharmacokinetic analysis of irinotecan in chemotherapy-naïve patients with glioblastoma. Ann Oncol 2003; 14: 603–14